US2016090353A1PendingUtilityA1

Prodrugs of gaba analogs, compositions and uses thereof

Assignee: XENOPORT INCPriority: Jun 11, 2001Filed: Dec 8, 2015Published: Mar 31, 2016
Est. expiryJun 11, 2021(expired)· nominal 20-yr term from priority
Inventors:Mark A. Gallop
A61P 25/32A61K 31/22C07C 229/28A61P 25/22A61P 25/08C07C 2601/18C07C 309/29A61P 25/00C07C 2601/14C07C 271/22C07C 2601/04A61K 31/24C07C 2101/04
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         n is 0; 
         each of R1, R3, R6 and R7 is hydrogen; 
         Y is oxygen; and 
         R4 and R5, together with the carbon atom to which they are attached, form a cyclobutyl ring that is substituted with an ethanyl-substituted C 2 -C 4  alkenyl moiety. 
       
     
     
         2 . The compound of  claim 1 , wherein the ethanyl-substituted C 2 -C 4  alkenyl moiety is an ethanyl-substituted propenyl moiety. 
     
     
         3 . The compound of  claim 2 , comprising a pharmaceutically acceptable salt. 
     
     
         4 . The compound of  claim 3 , wherein the salt is a benzene sulfonic acid salt. 
     
     
         5 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of  claim 1 . 
     
     
         6 . A method for treating epilepsy, depression, anxiety, psychosis, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, panic, pain, inflammatory disease, insomnia, gastrointestinal disorders or ethanol withdrawal syndrome in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of  claim 1 . 
     
     
         7 . The method of  claim 6 , comprising treating pain. 
     
     
         8 . The method of  claim 7 , comprising treating neuropathic pain. 
     
     
         9 . The method of  claim 6 , for treating anxiety. 
     
     
         10 . The method of  claim 6 , for treating epilepsy. 
     
     
         11 . A compound of Formula (XIII): 
       
         
           
           
               
               
           
         
         wherein each of R3 and R6 is hydrogen; 
         R4 and R5, together with the carbon atom to which they are attached, form a cyclobutyl ring that is substituted with an ethanyl-substituted C2-C4 alkenyl moiety. 
       
     
     
         12 . The compound of  claim 11 , comprising a pharmaceutically acceptable salt. 
     
     
         13 . The compound of  claim 12 , wherein the salt is a benzene sulfonic acid salt. 
     
     
         14 . A compound of Formula (XIII): 
       
         
           
           
               
               
           
         
         wherein each of R3 and R6 is hydrogen; 
         R4 and R5, form a substituted C4-C7 cycloalkyl that is a bicyclic. 
       
     
     
         15 . The compound of  claim 14 , comprising a pharmaceutically acceptable salt. 
     
     
         16 . The compound of  claim 14 , wherein the salt is a benzene sulfonic acid salt.

Join the waitlist — get patent alerts

Track US2016090353A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.